- Record: found
- Abstract: not found
- Article: not found
Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
S. RAMALINGAM, T Reungwetwattana, B Chewaskulyong, A Dechaphunkul, K.H. LEE, F. IMAMURA, N Nogami, Y Ohe, Y. CHENG, B.C. Cho
Read this article at
ScienceOpen
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.